Form 4 for APRE Aprea Therapeutics, Inc.

Accepted 2024-05-02 00:00:00 ET · period of report 2024-05-01 · accession 0001104659-24-056402 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2024-05-02	2024-05-01	APRE	Mirza Nadeem Q.	Chief Medical Off	A - Grant	$0.00	+6,730	6,730	New	$0
D	2024-05-02	2024-05-01	APRE	Mirza Nadeem Q.	Chief Medical Off	A - Grant	$0.00	+26.9K	26.9K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-05-01	A	A	6,730	$0.00	6,730	D	—	—	(F1) These shares were granted by the Issuer as an inducement material to the Reporting Person entering into employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4). These shares represent restricted stock units ("RSUs") and shall vest and be settled in the Issuer's common stock, on a one-for-one basis in three (3) equal annual installments beginning on May 1, 2025, until vested in full, subject to the Reporting Person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
2	Derivative	Stock Options (Right to Purchase)	2024-05-01	A	A	26,920	$0.00	26,920	D	$5.25 · — to 2034-05-01	29,920 Common Stock	(F2) The option was granted by the Issuer as an inducement material to the Reporting Person entering into employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4). Twenty-five percent of these options vest on May 1, 2025, with the remaining options vesting ratably over the following 36 months, subject to the Reporting Person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.